ACT Brief: Trial Representation and Design, CRO Revenue Recognition Risks, and Real-Time FDA Data Review

In today's ACT Brief, we examine how improving representation changes trial design at Merck, revenue recognition challenges in CRO contracts, and FDA's pilot program for real-time clinical data review.